Navigation Links
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Date:5/10/2013

ases GLP-1 and PYY, GI hormones associated with glycemic control and appetite. Lexicon is also developing LX4211 for type 2 diabetes with Phase 3 planning ongoing.

About Type 1 Diabetes

It is estimated that every year in the United States, more than 15,000 young people under the age of 20 years are diagnosed with type 1 diabetes mellitus. Type 1 diabetes is a disease caused by an autoimmune destruction of the insulin-producing beta-cells in the pancreas, resulting in an absolute insulin deficiency. Maintaining glycemic control is a key therapeutic goal in order to delay or prevent the complications of diabetes including retinopathy, nephropathy, neuropathy and macrovascular disease. Insulin use to maintain tight glycemic control presents significant challenges for patients, both logistically and medically, with constant approximations and adjustments made to accommodate various meals and activity levels.  Despite advances in insulin therapy (fast-acting mealtime analogs, long-acting basal analogs, and insulin pump therapy) and glycemic monitoring (continuous glucose monitoring), tight glycemic control is still associated with hypoglycemia.  A new therapy used in combination with insulin that offers the advantages of improved glycemic control, reduced and simpler insulin regimen, and lower incidence of hypoglycemia would offer a significant advancement in therapy for this serious chronic disease which still results in excess morbidity and mortality.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focuse
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... South Carolina , May 29, 2015 ... have announced a collaboration designed to provide therapeutic clinical ... majority of cancer patients living in U.S. communities. ... Health to harness the power of big data and ... thousands of patients to enable ,accrual on demand, for ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/29/2015)... YORK , May 29, 2015  World-renowned prostate surgeon ... new findings on the benefit of MR/Ultrasound Fusion-Guided Biopsy ... "Our Prostate Cancer Center at Lenox Hill ... Fusion Biopsy System in New York City ... and low risk prostate cancers. The use of an MRI ...
Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
(Date:5/29/2015)... San Diego, California (PRWEB) May 29, 2015 ... Common Core” and have joined the national effort to teach ... Many parents in the U.S. have been “sickened” by the ... country. However, love it or hate it, Common Core is ... the District of Columbia. Parents are now seeking ways ...
(Date:5/29/2015)... May 29, 2015 Intermountain ... partnered with Stratus Video Interpreting ... facilitate better communication and timely care for ... hearing loss. Stratus’ video remote interpreting (VRI) ... enabling staff to quickly access qualified medical ...
(Date:5/29/2015)... York, NY (PRWEB) May 29, 2015 ... USA Today, with a circulation of approximately 250,000 and ... distributed nationally, through a vast social media strategy, and ... outlets. To explore the digital version of the campaign, ... cover of the print publication. Inside, the actress, model ...
(Date:5/29/2015)... York, NY (PRWEB) May 29, 2015 ... on the “beauty of protection”. Skin Health is ... USA Today within the markets of New York, Los ... an estimated 750,000 readers. Its digital counterpart will reach ... content hubs. To read more the Skin Health campaign ...
(Date:5/29/2015)... OncLive proudly announces the 2015 ... recognized by a panel of eminent oncologists for landmark ... Honorees will be introduced and celebrated TONIGHT at the ... 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 ... recognized for groundbreaking accomplishments, in fields including translational research, ...
Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4
... successfully modified a common plant virus to deliver drugs ... affecting surrounding tissue. These tiny "smart bombs" - each ... a human hair - could lead to more effective ... effects. , Drs. Stefan Franzen, professor of chemistry, and ...
... Worldwide, Inc., an accredited provider of continuing medical education ... an online repository of resources and education on the ... health care practitioners.The goal of Managing Myeloma ... provide an extensive array of programs to support clinical ...
... first of its kind Global,Consumer Study is here! ... that,compares consumer trends in 15 countries. ISPA, working ... France,Germany, India, Italy, Japan, Russia, Singapore, Spain, Thailand, UK ... information on why people,spa in the 2008 Global Consumer ...
... body quickly needs to restore the vital blood volume. This ... the bone marrow. These hematopoietic stem cells remain dormant throughout ... of injury and loss of blood. Then they immediately start ... This has recently been shown by a group of scientists ...
... 12 Cardium Therapeutics (NYSE Alternext US: CXM) ... that InnerCool,s CoolBlue surface temperature modulation system was ... Chicago,s NBC 5 News. The story can ... segment features a maternity patient who suffered cardiac ...
... article published in the February 11 issue of the ... physicians to better understand what constitutes quality hospice and ... be best for their patients. Options for care at ... With more than 1,400 hospital-based palliative care programs ...
Cached Medicine News:Health News:Nanoparticle 'smart bomb' targets drug delivery to cancer cells 2Health News:Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists 2Health News:Worldwide, Stress is the No.1 Reason People Spa 2Health News:Stem cells: Deathly awakening by interferon 2Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 2Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 3Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 4Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 5Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 6Health News:TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago 7Health News:JAMA Article Provides Guidance to Physicians on End-of-Life Care 2
Inquire...
... Liquichek Specialty Immunoassay Control ... assayed control designed to ... and Liquichek Immunoassay Plus ... specially formulated to include ...
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: